Primo Brands Corporation (NYSE:PRMB) is among the best US stocks to buy under $20. On November 25, Bonnie Herzog, an analyst at Goldman Sachs, trimmed the price target on Primo Brands Corporation (NYSE:PRMB) to $18 from $21, while maintaining a Neutral stance on the stock, according to TheFly. In a research note, the analyst raised concerns regarding the sales decline, which she believes will be faster and more prolonged than anticipated. With respect to that, the firm expects incremental headwinds for the ...

StubHub Holdings, Inc. (NYSE:STUB) is among the best US stocks to buy under $20. As of November 26, StubHub Holdings, Inc. (NYSE:STUB) is a strong Buy, with around two-thirds of analysts covering it assigning a Buy or equivalent rating. With a consensus 1-year median price target of $25, the stock has an upside of over 126%. According to TheFly, BofA downgraded StubHub Holdings, Inc. (NYSE:STUB) to Neutral from Buy on November 14, with a reduced price target of $19 from $25. The revised price target, whic ...

Primo Brands Corporation (NYSE:PRMB) is one of the best upside stocks to buy now. On November 26, Barclays analyst Lauren Lieberman lowered the firm’s price target on Primo Brands to $24 from $25 and maintained an Overweight rating on the shares. The company’s exit rate and revenue mix are expected to create a greater difficulty for its direct delivery business in 2026 than Barclays had previously anticipated. Primo Brands reported its Q3 2025 earnings earlier in the same month, revealing a quarter charac ...

Group 1 - Dyne Therapeutics has been identified as a promising investment opportunity, with Bernstein raising its price target from $12 to $21, indicating a favorable risk-reward profile [1] - The company is expected to release significant data for its treatment candidate DYN-251 for Duchenne Muscular Dystrophy (DMD), which is anticipated to be a major catalyst for the stock [1][3] - Dyne Therapeutics reported in its Q3 2025 earnings that both of its lead programs, DYNE-251 for DMD and DYNE-101 for Myotonic Dystrophy Type 1, received Breakthrough Therapy Designation from the FDA, highlighting the potential of its FORCE platform [2] Group 2 - Dyne Therapeutics plans to launch two potentially best-in-class medicines within approximately one year, starting with DYNE-251 for DMD, with topline data from a primary analysis expected in December 2025 [3] - The company aims to support a potential submission for US Accelerated Approval in Q2 2026 based on the upcoming data [3]

Flutter Entertainment (NYSE:FLUT) is one of the best upside stocks to buy now. On November 28, Citi analyst Ben Shelley lowered the firm’s price target on Flutter Entertainment to $320 from $340 with a Buy rating on the shares. This sentiment was announced as Citi stated that the uncertainty surrounding a potential UK tax increase acted as a significant overhang on Flutter’s equity for almost 4 months. Although the actual UK tax hike is more substantial than initially anticipated, Shelley believes that thi ...

Under Armour Inc. (NYSE:UA) ranks among the best short squeeze stocks to buy right now. Telsey Advisory Group announced on November 18 that Under Armour Inc. (NYSE:UA) and basketball player Stephen Curry will part ways in 2026 after a 12-month wind-down period. The firm reiterated its Market Perform rating and $5 price target for the company’s shares. The basketball division of Under Armour, which includes the Curry brand, is expected to generate around $100 million – $120 million in revenue during the c ...

The Boeing Company (NYSE:BA) is among the 10 Best Drone Stocks to Buy Right Now. On November 26, the company announced that it had secured a contract worth $4.7 billion from the U.S. Army to manufacture AH-64E Apache attack helicopters for international clients, of which 96 units will be produced for Poland. The Boeing Company (BA) Secures $4.7 Billion Contract To Build AH-64E Apache Helicopters For International Clients Pixabay/Public Domain This is the largest contract in terms of volume for the aircr ...

Group 1 - Novartis AG is recognized as a strong slow growth stock, with a projected sales CAGR of 6% from 2024 to 2029, supported by recent meetings with TD Cowen [1][2] - Key growth contributors include existing medicines such as Cosentyx, Pluvicto, Kisqali, Leqvio, Kesimpta, and Scemblix, which are expected to mitigate the impact of generic erosion, particularly for Entresto [2] - The company has a robust position in immunology with products like Rhapsido and ianalumab, which are considered "substantially de-risked" and likely to contribute to growth before 2030 [2] Group 2 - Novartis revised its mid-term sales target for 2025-2030 to a CAGR of 5-6% in constant currencies and aims to achieve margins above 40% by 2029, despite a projected 1-2 percentage points dilution from the acquisition of Avidity Biosciences [3] - The company is focused on discovering, developing, and manufacturing innovative treatments aimed at improving and extending lives while addressing serious diseases [4]

Group 1 - Analog Devices, Inc. (NASDAQ:ADI) is recognized as a strong slow growth stock, with Benchmark reaffirming its Buy rating and maintaining a price target of $285 following the company's fourth-quarter results [1][2] - The company's fourth-quarter revenue reached $3.08 billion, surpassing projections of $3.01 billion, and adjusted earnings per share (EPS) were $2.26, exceeding the expected $2.22 [2] - For the first quarter of fiscal 2026, Analog Devices anticipates revenue of $3.1 billion, an operating margin of 43.5%, and an expected EPS of $2.29 [2] Group 2 - Benchmark indicates that most of Analog Devices' end markets have bottomed out and are beginning to recover, setting the stage for significant growth in fiscal year 2026 [3] - Despite some concerns regarding seasonal consumer business and first-quarter automotive performance, Benchmark believes Analog Devices is well-positioned for long-term growth and cyclical recovery [3] - Analog Devices specializes in integrated circuits (ICs), software, and subsystems products, indicating a focus on technology and innovation within the semiconductor industry [4]

The Home Depot, Inc. (NYSE:HD) ranks among the best slow growth stocks to invest in. On November 19, TD Cowen retained its Buy rating on The Home Depot, Inc. (NYSE:HD) but lowered its price target from $470 to $410. The adjustment followed Home Depot’s third-quarter result, which fell short of Street expectations, alongside a reduction in the fourth-quarter forecast and a shift in the company’s macroeconomic outlook. Rob Wilson / Shutterstock.com The Home Depot, Inc. (NYSE:HD) reduced its outlook for fu ...